Your browser doesn't support javascript.
loading
Treatment adherence and BMI reduction are key predictors of HbA1c 1 year after diagnosis of childhood type 2 diabetes in the United Kingdom.
Candler, Toby P; Mahmoud, Osama; Lynn, Richard M; Majbar, Abdalmonen A; Barrett, Timothy G; Shield, Julian P H.
Afiliação
  • Candler TP; NIHR Biomedical Research Centre: Nutrition, Diet and Lifestyle Theme, School of Oral and Dental Sciences, University of Bristol, Bristol, UK.
  • Mahmoud O; Nutrition Theme, MRC The Gambia at London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
  • Lynn RM; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Majbar AA; Department of Applied Statistics, Helwan University, Helwan, Egypt.
  • Barrett TG; British Paediatric Surveillance Unit, Royal College of Paediatrics and Child Health, London, UK.
  • Shield JPH; NIHR Biomedical Research Centre: Nutrition, Diet and Lifestyle Theme, School of Oral and Dental Sciences, University of Bristol, Bristol, UK.
Pediatr Diabetes ; 19(8): 1393-1399, 2018 12.
Article em En | MEDLINE | ID: mdl-30175430
ABSTRACT
BACKGROUND/

OBJECTIVE:

Type 2 Diabetes (T2DM) is increasing in childhood especially among females and South-Asians. Our objective was to report outcomes from a national cohort of children and adolescents with T2DM 1 year following diagnosis.

METHODS:

Clinician reported, 1-year follow-up of a cohort of children (<17 years) diagnosed with T2DM reported through the British Paediatric Surveillance Unit (BPSU) (April 2015-April 2016).

RESULTS:

One hundred (94%) of 106 baseline cases were available for review. Of these, five were lost to follow up and one had a revised diagnosis. Mean age at follow up was 15.3 years. Median BMI standard deviation scores (SDS) was 2.81 with a decrease of 0.13 SDS over a year. HbA1c <48 mmol/mol (UK target) was achieved in 38.8%. logHbA1c was predicted by clinician reported compliance and attendance concerns (ß = 0.12, P = <0.0001) and change in body mass index (BMI) SDS at 1-year (ß = 0.13, P=0.007). In over 50%, clinicians reported issues with compliance and attendance. Mean clinic attendance was 75%. Metformin was the most frequently used treatment at baseline (77%) and follow-up (87%). Microalbuminuria prevalence at 1-year was 16.4% compared to 4.2% at baseline and was associated with a higher HbA1c compared to those without microalbuminuria (60 vs 49 mmol/mol, P = 0.03).

CONCLUSIONS:

Adherence to treatment and a reduction in BMI appear key to better outcomes a year after T2DM diagnosis. Retention and clinic attendance are concerning. The prevalence of microalbuminuria has increased 4-fold in the year following diagnosis and was associated with higher HbA1c.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Redução de Peso / Índice de Massa Corporal / Diabetes Mellitus Tipo 2 / Cooperação e Adesão ao Tratamento Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Child / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemoglobinas Glicadas / Redução de Peso / Índice de Massa Corporal / Diabetes Mellitus Tipo 2 / Cooperação e Adesão ao Tratamento Tipo de estudo: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Child / Female / Humans / Male País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article